A Company Focused on Monetizing Assets and Creating Breakthrough Therapies
Omni Bio Pharmaceutical, Inc. (OTC: OMBP) is an emerging biopharmaceutical company that was founded on a monetization strategy for licensing issued and pending patents for new uses of an existing FDA-approved drug, alpha-1 antitrypsin (AAT). We have been funding sponsored research, supporting clinical trials and collaborating with existing AAT manufacturers to further these efforts.
More recently, we have advanced our strategy to create a patent-protected pipeline of recombinant Fc fusion molecules of alpha-1 antitrypsin (Fc-AATs) that are targeted for the treatment of a variety of serious immunological diseases, including Type 1 diabetes, bone marrow transplantation rejection (graft vs host disease), treatment-refractory gout, and inflammatory bowel disease.
Learn more about alpha-1 antitrypsin (AAT)
Zacks Small-Cap Research Initiates Coverage of Omni Bio
June 3, 2013 VIEW Report
Zacks Small-Cap Research Releases Analyst Report of Omni Bio
April 11, 2013 VIEW Report
New Company Overview Highlights Fc-AAT Data in Gouty Arthritis Animal Model
March 26, 2013 VIEW
Omni Bio Announces First Results for Its Lead Recombinant Molecule
March 15, 2013 VIEW Press Release
Omni Bio Pharmaceutical Appoints Dr. Michael Kamarck as New Director
February 6, 2013 VIEW Press Release
Omni Bio Video
Watch this video to learn more about Omni Bio's breakthrough research for plasma and synthetic Alpha-1 Antitrypsin (AAT).
Dr. Charles Dinarello discusses article he co-authored in Blood Magazine